CSF neopterin as marker of disease activity in multiple sclerosis.

Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.47

Evidence for increased nitric oxide production in multiple sclerosis. J Neurol Neurosurg Psychiatry (1995) 1.03

Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler (2012) 0.99

Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation (2013) 0.95

Cerebrospinal fluid. J Neurol Neurosurg Psychiatry (1995) 0.94

Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Med (2013) 0.93

Paving the path to HIV neurotherapy: Predicting SIV CNS disease. Eur J Pharmacol (2015) 0.88

Expression of urokinase plasminogen activator receptor on monocytes from patients with relapsing-remitting multiple sclerosis: effect of glatiramer acetate (copolymer 1). Clin Diagn Lab Immunol (2001) 0.86

Neopterin production and tryptophan degradation during 24-months therapy with interferon beta-1a in multiple sclerosis patients. J Transl Med (2011) 0.77

A plasma diagnostic model of human T-cell leukemia virus-1 associated myelopathy. Ann Clin Transl Neurol (2015) 0.75

Serum Immune System Biomarkers Neopterin and Interleukin-10 Are Strongly Related to Tryptophan Metabolism in Healthy Young Adults. J Nutr (2016) 0.75

Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler (1999) 4.91

Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest (1977) 4.63

COBAS AMPLICOR: fully automated RNA and DNA amplification and detection system for routine diagnostic PCR. Clin Chem (1996) 3.17

A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood (1999) 2.98

What do commercial ginseng preparations contain? Lancet (1994) 2.94

Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation (1990) 2.89

Changes in job strain in relation to changes in physiological state. A longitudinal study. Scand J Work Environ Health (1988) 2.57

Immunoglobulins in multiple sclerosis and infections of the nervous system. Arch Neurol (1971) 2.51

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet (1996) 2.06

Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic Escherichia coli. N Engl J Med (1988) 2.04

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer (2004) 2.03

Economic analysis of a randomized clinical trial to compare filgrastim-mobilized peripheral-blood progenitor-cell transplantation and autologous bone marrow transplantation in patients with Hodgkin's and non-Hodgkin's lymphoma. J Clin Oncol (1997) 2.02

Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest (1977) 2.02

Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry (1994) 1.98

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer (2006) 1.96

Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain (2001) 1.78

[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74

T and B cell responses to myelin-oligodendrocyte glycoprotein in multiple sclerosis. J Immunol (1991) 1.65

Immune function in unemployed women. Psychosom Med (1987) 1.65

Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis. Eur J Neurol (2000) 1.61

Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry (2006) 1.61

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs. Mult Scler (2012) 1.59

Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest (1990) 1.57

Techno-stress. A psychophysiological study of employees with VDU-associated skin complaints. J Occup Med (1992) 1.55

Early diagnosis of tuberculous meningitis by detection of anti-BCG secreting cells in cerebrospinal fluid. Lancet (1990) 1.55

Increased incidence of Guillain-Barré syndrome postpartum. Epidemiology (1998) 1.53

Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Mult Scler (2011) 1.51

Neutralization of macrophage inflammatory protein 2 (MIP-2) and MIP-1alpha attenuates neutrophil recruitment in the central nervous system during experimental bacterial meningitis. Infect Immun (1999) 1.48

Comparison of antibodies against different viruses in cerebrospinal fluid and serum samples from patients with multiple sclerosis. Infect Immun (1974) 1.48

Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens (2004) 1.47

Guillain-Barré syndrome in south-west Stockholm, 1973-1991, 1. Quality of registered hospital diagnoses and incidence. Acta Neurol Scand (1995) 1.46

Altered surface marker expression and function of G-CSF-induced neutrophils from test subjects and patients under chemotherapy. Br J Haematol (1994) 1.45

Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood (1993) 1.45

Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol (2007) 1.44

Measles virus antibodies in multiple sclerosis. Comparison of antibody titers in cerebrospinal fluid and serum. Arch Neurol (1974) 1.44

Cytokine autoantibodies in multiple sclerosis, aseptic meningitis and stroke. Eur J Clin Invest (1998) 1.44

The B cell repertoire in experimental allergic neuritis involves multiple myelin proteins and GM1. J Neurol Sci (1994) 1.43

Atrial natriuretic peptide ANP(1-98) and ANP(99-126) in patients with severe chronic congestive heart failure: relation to echocardiographic measurements. A subgroup analysis from the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). J Card Fail (1995) 1.41

Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol (2000) 1.40

Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Br J Haematol (1996) 1.40

Immunoglobulin abnormalities in multiple sclerosis. Relation to clinical parameters: exacerbations and remissions. Arch Neurol (1973) 1.40

Identification of mono- and dihydroxy bile acids in human feces by gas-liquid chromatography and mass spectrometry. J Lipid Res (1966) 1.37

Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol (2000) 1.37

Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. Proc Natl Acad Sci U S A (1989) 1.36

Autoreactive T and B cells responding to myelin proteolipid protein in multiple sclerosis and controls. Eur J Immunol (1991) 1.36

Immunoglobulins and measles antibodies in subacute sclerosing panencephalitis. Arch Neurol (1973) 1.35

Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden. Eur J Neurol (2001) 1.34

Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. Ann Neurol (1994) 1.33

Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia. European APL group. Leukemia (2000) 1.31

Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res (1996) 1.30

Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis. J Immunol (2001) 1.30

Cerebrospinal fluid and serum immunoglobulins and antibody titers in mumps meningitis and aseptic meningitis of other etiology. Infect Immun (1978) 1.28

Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology (1998) 1.26

Innovative mentoring programs to promote gender equity in academic medicine. Acad Med (2001) 1.23

Immunoglobulins and measles antibodies in optic neuritis. N Engl J Med (1973) 1.22

CD16- CD56+ natural killer cells after bone marrow transplantation. Blood (1992) 1.21

Characterization of antibody activity in oligoclonal immunoglobulin G synthesized within the central nervous system in a patient with tuberculous meningitis. J Clin Microbiol (1981) 1.20

Short-term effects of early suckling and touch of the nipple on maternal behaviour. Early Hum Dev (1990) 1.19

Circulating CD4+CD25+ and CD4+CD25+ T cells in myasthenia gravis and in relation to thymectomy. Scand J Immunol (2004) 1.18

Multiple sclerosis: disturbed kappa: lambda chain ratio of immunoglobulin G in cerebrospinal fluid. Clin Exp Immunol (1970) 1.18

Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke (1999) 1.18

Principles of albumin and IgG analyses in neurological disorders. II. Relation of the concentration of the proteins in serum and cerebrospinal fluid. Scand J Clin Lab Invest (1977) 1.17

IgG production within the central nervous system: a critical review of proposed formulae. Ann Neurol (1985) 1.17

Antimyelin basic protein and antimyelin antibody-producing cells in multiple sclerosis. Ann Neurol (1990) 1.17

Suppression of experimental autoimmune myasthenia gravis by nasal administration of acetylcholine receptor. J Neuroimmunol (1995) 1.17

Respiratory syncytial virus stimulation of vascular endothelial cell growth Factor/Vascular permeability factor. Am J Respir Cell Mol Biol (2000) 1.17

Comparison of electrophoresis on agar gel and agarose gel in the evaluation of gamma-globulin abnormalities in cerebrospinal fluid and serum in multiple sclerosis. Clin Chim Acta (1973) 1.17

Cytotonic enterotoxin from Aeromonas hydrophila. Toxicon (1982) 1.16

Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol (1997) 1.16

Seasonal patterns in optic neuritis and multiple sclerosis: a meta-analysis. J Neurol Sci (2000) 1.16

Suppression of experimental autoimmune myasthenia gravis by oral administration of acetylcholine receptor. J Neuroimmunol (1993) 1.15

Persistence of tropical ataxic neuropathy in a Nigerian community. J Neurol Neurosurg Psychiatry (2000) 1.13

Age-specific prevalence of antibody to enterotoxigenic Escherichia coli in Ecuadorian and German children. J Infect Dis (1990) 1.12

Improved detection of oligoclonal IgG in cerebrospinal fluid by isoelectric focusing in agarose, double-antibody peroxidase labeling, and avidin-biotin amplification. Clin Chem (1984) 1.12

Antibodies to myelin-oligodendrocyte glycoprotein in cerebrospinal fluid from patients with multiple sclerosis and controls. J Neuroimmunol (1991) 1.11

Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol (2001) 1.11

The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis. Genes Immun (2001) 1.11

Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood (1998) 1.10

Expression of nitric oxide synthases in subcutaneous adipose tissue of nonobese and obese humans. J Lipid Res (2000) 1.09

A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer. Ann Oncol (2011) 1.08

Characterization of trisubstituted cholanoic acids in human feces. J Lipid Res (1966) 1.08

Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J Immunol (1999) 1.07

Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patients. Br J Haematol (1996) 1.07

Job strain variations in relation to plasma testosterone fluctuations in working men--a longitudinal study. J Intern Med (1990) 1.07

Increased levels of interferon-gamma (IFN-gamma), IL-4 and transforming growth factor-beta (TGF-beta) mRNA expressing blood mononuclear cells in human HIV infection. Clin Exp Immunol (1994) 1.07

Myelin antigen reactive T cells in cerebrovascular diseases. Clin Exp Immunol (1992) 1.07

Mechanisms of nasal tolerance induction in experimental autoimmune myasthenia gravis: identification of regulatory cells. J Immunol (1999) 1.06

Production of discrete changes in dopamine and noradrenaline levels and turnover in various parts of the rat brain following exposure to xylene, ortho-, meta-, and para-xylene, and ethylbenzene. Toxicol Appl Pharmacol (1981) 1.05

Increased mRNA expression of IL-6, IL-10, TNF-alpha, and perforin in blood mononuclear cells in human HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.05

Oligoclonal Borrelia burgdorferi-specific IgG antibodies in cerebrospinal fluid in Lyme neuroborreliosis. J Infect Dis (1990) 1.05

Relation between benign course of multiple sclerosis and low-grade humoral immune response in cerebrospinal fluid. J Neurol Neurosurg Psychiatry (1980) 1.05

Continuous infusion of growth hormone feminizes hepatic steroid metabolism in the rat. Endocrinology (1981) 1.05

Neuroendocrine and immunologic effects of unemployment and job insecurity. Psychother Psychosom (1991) 1.05

Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. J Neuroimmunol (1998) 1.04

IL-17 and IFN-gamma mRNA expression is increased in the brain and systemically after permanent middle cerebral artery occlusion in the rat. J Neuroimmunol (2001) 1.04

Pulmonary infiltrations in febrile patients with neutropenia. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer (1994) 1.04